Growth differentiation factor‐6 attenuates inflammatory and pain‐related factors and degenerated disc‐induced pain behaviors in rat model

Haowen Cui,Jian Zhang,Zemin Li,Fan Chen,Haitao Cui,Xianfa Du,Hui Liu,Jianru Wang,Ashish D. Diwan,Zhaomin Zheng
DOI: https://doi.org/10.1002/jor.24793
2020-09-14
Journal of Orthopaedic Research
Abstract:<p>Previous studies have indicated that growth differentiation factor 6 (GDF6) is a potential candidate for intervertebral disc (IVD) degeneration (IDD) treatment. Here, we investigated the effect of GDF6 on IDD by examining changes in disc structure and the expression of inflammatory and pain‐related factors. A rat posterior disc puncture model of single segments and three consecutive segments was constructed, and GDF6 or PBS was administered via intradiscal injection 1 or 2 weeks after surgery. Magnetic resonance imaging showed a clear degeneration signal in the punctured disc, which was inhibited by GDF6. Histological staining revealed that GDF6 did not significantly improve the structure of IVDs in rats 8 weeks after puncture surgery, but it had an inhibitory effect on expression of the TNF‐α and IL‐1β in the IVD. Furthermore, GDF6 was found to protect the morphology and structure of the IVD 32 weeks after surgery. Mechanical and thermal hyperalgesia tests suggested that GDF6 injection can significantly improve mechanical and thermal‐stimulated pain behavior in rats and inhibit the expression of inflammatory factors TNF‐α and IL‐1β and the pain factor calcitonin gene‐related peptide in the dorsal root ganglion. A rat protein array test indicated that GDF6 could reduce the expression of cytokines IL‐6, ICAM1, MMP‐13, IL‐1β, and TNF‐α and increase the expression of TIMP1, TGF‐β2, IL‐10, and resistin in a TNF‐α‐induced IDD cell model. Thus, our study demonstrates that GDF6 can improve the structure of the IVD, inhibit the expression of inflammatory and pain‐related factors, and improve pain behavior in rats.</p><p><b>Statement of Clinical Significance </b>: To establish further pre‐clinical research and clinical trials, comprehensive data are needed to validate the regenerative properties of GDF6. Ideally, a regenerative agent should also be able to relieve discogenic pain, achieving the best clinical outcomes.</p><p>This article is protected by copyright. All rights reserved.</p>
orthopedics
What problem does this paper attempt to address?